Medy-Tox won regulatory clearance to sell two facial fillers in the United Arab Emirates, marking its latest push to expand beyond its South Korean home market.
The UAE’s Ministry of Health and Prevention approved Neuramis Deep Lidocaine and Neuramis Volume Lidocaine, the company said Tuesday. The products, which use hyaluronic acid technology, have already secured European Union certification.
The move puts Medy-Tox in direct competition with established European brands in the Gulf region’s lucrative beauty market. The company plans to distribute the products through local partner BND Bio Drug Store LLC, while also seeking approval for its botulinum toxin formulation, Neuronox.
The Seoul-based biotech firm is betting on growing regional demand for Korean beauty products to help drive sales. Its Neuramis line, currently sold in 35 countries, uses FDA-registered ingredients and claims enhanced durability with reduced side effects compared to competitors.
The UAE approval could serve as a gateway to wider Middle Eastern expansion for Medy-Tox, which has spent a decade building clinical data to support its filler technology. The company is targeting additional product launches in the region by year-end.
